Media coverage about Brainstorm Cell Therapeutics (NASDAQ:BCLI) has been trending somewhat positive this week, Alpha One reports. The research group, a subsidiary of Accern, ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Brainstorm Cell Therapeutics earned a coverage optimism score of 0.11 on Alpha One’s scale. Alpha One also assigned news stories about the biotechnology company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have effected Alpha One Sentiment’s rankings:
- Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI)’s Stock … – KL Daily (kldaily.com)
- Brainstorm Cell Therapeutics Inc. to Post Q2 2017 Earnings of ($0.10) Per Share, Zacks Investment Research Forecasts (BCLI) (americanbankingnews.com)
- BCLI: Phase 3 Trial of NurOwn® in Final Stages of Preparation (finance.yahoo.com)
- How Analysts Feel About Brainstorm Cell Therapeutics Inc (BCLI) After Today’s Huge Increase? – Weekly Register (weeklyregister.com)
- BrainStorm to Provide Corporate Update at the BIO International Convention (finance.yahoo.com)
Brainstorm Cell Therapeutics (NASDAQ:BCLI) traded up 3.03% during midday trading on Friday, reaching $4.42. The company’s stock had a trading volume of 114,556 shares. The stock’s 50 day moving average is $4.08 and its 200 day moving average is $3.52. The stock’s market cap is $82.81 million. Brainstorm Cell Therapeutics has a 12-month low of $2.06 and a 12-month high of $5.10.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its earnings results on Monday, May 15th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.20. Analysts anticipate that Brainstorm Cell Therapeutics will post ($0.79) earnings per share for the current year.
Separately, Maxim Group set a $8.00 price target on shares of Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a report on Tuesday.
ILLEGAL ACTIVITY WARNING: “Brainstorm Cell Therapeutics (BCLI) Earns Daily Media Impact Rating of 0.11” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://transcriptdaily.com/2017/06/17/brainstorm-cell-therapeutics-bcli-earns-daily-media-impact-rating-of-0-11.html.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.